Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of polyglutamine repeats in autosomal dominant Parkinson's disease.

Neurobiology of aging - 1 Jul 2014

Yamashita Chikara, Tomiyama Hiroyuki, Funayama Manabu, Inamizu Saeko, Ando Maya, Li Yuanzhe, Yoshino Hiroyo, Araki Takehisa, Ichikawa Tadashi, Ehara Yoshiro, Ishikawa Kinya, Mizusawa Hidehiro, Hattori Nobutaka

Abstract excerpt

We evaluated the contributions of various polyglutamine (polyQ) disease genes to Parkinson's disease (PD). We compared the distributions of polyQ repeat lengths in 8 common genes (ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, TBP, ATN1, and HTT) in 299 unrelated patients with autosomal dominant PD (ADPD)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Ataxins
Share to Genes, Dominant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Association Studies

Share to Nerve Tissue Proteins

Share to Parkinson Disease

Share to Peptides

Share to Repetitive Sequences, Amino Acid

Source

Identifiers

PMID: 24534762
DOI: 10.1016/j.neurobiolaging.2014.01.022

Genes

ATXN2
ATXN1
ATXN3
ATN1
ATXN7
HTT
TBP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24534762-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of polyglutamine repeats in autosomal dominant Parkinson's disease.PMID 24534762Read ↗

Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosisSemantic proximity Read ↗

Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders.Semantic proximity Read ↗

Ataxin-2 intermediate-length polyglutamine expansions in European ALS patientsSemantic proximity Read ↗

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of NeurodegenerationSemantic proximity Read ↗

The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.Semantic proximity Read ↗

Ataxin-2 repeat-length variation and neurodegenerationSemantic proximity Read ↗

PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.Semantic proximity Read ↗

Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.Semantic proximity Read ↗

Unbiased human genomic characterization of polyglutamine disorder genes to guide biological understanding and therapeutic strategiesSemantic proximity Read ↗

Polyglutamine (PolyQ) Diseases: Genetics to TreatmentsSemantic proximity Read ↗

Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.Semantic proximity Read ↗

Juvenile Huntington’s Disease and Other PolyQ diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic DataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.